David P. Schenkein
CIK: 0001578200
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Jun 5, 2026PRME
Prime Medicine, Inc.
Award(A)DirectStock Option (right to buy)
75K shares- - Jun 3, 2026DNLI
Denali Therapeutics Inc.
Award(A)Direct6.4K shares- - Jan 2, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Award(A)Direct155 shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
Award(A)DirectStock Option (right to buy)
39.1K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
Award(A)DirectStock Option (right to buy)
45K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
Disposition(D)DirectStock Option (right to buy)
45K shares- - Aug 1, 2025PRME
Prime Medicine, Inc.
Disposition(D)DirectStock Option (right to buy)
39.1K shares- - Jun 4, 2025PRME
Prime Medicine, Inc.
Award(A)DirectStock Option (right to buy)
55K shares- - Jun 3, 2025DNLI
Denali Therapeutics Inc.
Award(A)Direct6K shares- - Jan 2, 2025REGN
REGENERON PHARMACEUTICALS, INC.
Award(A)Direct166 shares- - Nov 11, 2024DNLI
Denali Therapeutics Inc.
Sale(S)Direct32.3K shares at avg. $32.87$1.1M - Nov 11, 2024DNLI
Denali Therapeutics Inc.
Sale(S)Direct27.1K shares at avg. $32.09$871K - Nov 11, 2024DNLI
Denali Therapeutics Inc.
Exercise(M)Direct47.2K shares at avg. $18.00$849K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 5, 2026 |  PRME Prime Medicine, Inc. | Award(A) Stock Option (right to buy) | 75,000 | - | - | Direct |
| Jun 3, 2026 |  DNLI Denali Therapeutics Inc. | Award(A) | 6,408 | - | $0 | Direct |
| Jan 2, 2026 |  REGN REGENERON PHARMACEUTICALS, INC. | Award(A) | 155 | - | $0 | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Award(A) Stock Option (right to buy) | 39,062 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Award(A) Stock Option (right to buy) | 45,000 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Disposition(D) Stock Option (right to buy) | 45,000 | - | - | Direct |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | Disposition(D) Stock Option (right to buy) | 39,062 | - | - | Direct |
| Jun 4, 2025 | PRME Prime Medicine, Inc. | Award(A) Stock Option (right to buy) | 55,000 | - | - | Direct |
| Jun 3, 2025 | DNLI Denali Therapeutics Inc. | Award(A) | 6,037 | - | - | Direct |
| Jan 2, 2025 | REGN REGENERON PHARMACEUTICALS, INC. | Award(A) | 166 | - | $0 | Direct |
| Nov 11, 2024 | DNLI Denali Therapeutics Inc. | Sale(S) | 32,312 | $32.87 | $1,062,095 | Direct |
| Nov 11, 2024 | DNLI Denali Therapeutics Inc. | Sale(S) | 27,129 | $32.09 | $870,570 | Direct |
| Nov 11, 2024 | DNLI Denali Therapeutics Inc. | Exercise(M) | 47,165 | $18.00 | $848,970 | Direct |
1-13 of 13 transactions
About Schenkein David P
Schenkein David P (SEC CIK 0001578200) files insider reports with the SEC as Director of Prime Medicine, Inc. (PRME), Director of Denali Therapeutics Inc. (DNLI) and Director of REGENERON PHARMACEUTICALS, INC. (REGN).
Signal8 holds 8 ownership filings by Schenkein David P, all Form 4s, filed between Nov 13, 2024 and Jun 8, 2026. Those filings report 13 transactions, from Nov 11, 2024 to Jun 5, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Schenkein David P's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Schenkein David P
- Jun 5, 2026: Grant or award of PRME derivative securities (Form 4, code A).
- Jun 3, 2026: Grant or award of DNLI shares (Form 4, code A).
- Jan 2, 2026: Grant or award of REGN shares (Form 4, code A).
- Aug 1, 2025: Grants or awards of PRME derivative securities (2 lines, Form 4, code A).
- Aug 1, 2025: Disposition to issuer transactions of PRME derivative securities (2 lines, Form 4, code D).
Other insiders filing for Prime Medicine, Inc. (PRME)
- Marrazzo Jeffrey D, Director
- NELSEN ROBERT, Director
- Kelly Michael Aaron, Director
- Foster-Cheek Kaye I, Director
- Chung Wendy, Director
- Cahill Thomas, Director